According to our study, expression levels of LPCAT1 were strongly associated with amplifications of HER2 and MYC, negative ER and PR status and PTEN deletions, which are all linked to adverse tumor features and poor patient outcome. This evidence concerns the gene ERBB2 and neoplasm.